Who are Methylphenidate extended-release; Atomoxetine's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/methylphenidate-extended-release-atomoxetine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Methylphenidate extended-release; Atomoxetine — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Methylphenidate extended-release; Atomoxetine (Methylphenidate extended-release; Atomoxetine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine). Area: Psyc

marketed Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine) Dopamine transporter and norepinephrine transporter (methylphenidate); norepinephrine transporter (atomoxetine) Psychiatry / Neurology Small molecule Live · refreshed every 30 min

Target snapshot

Methylphenidate extended-release; Atomoxetine (Methylphenidate extended-release; Atomoxetine) — McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.. Methylphenidate is a central nervous system stimulant that increases dopamine and norepinephrine activity, while atomoxetine is a selective norepinephrine reuptake inhibitor.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Methylphenidate extended-release; Atomoxetine TARGET	Methylphenidate extended-release; Atomoxetine	McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.	marketed	Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine)	Dopamine transporter and norepinephrine transporter (methylphenidate); norepinephrine transporter (atomoxetine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Central nervous system stimulant (methylphenidate); selective norepinephrine reuptake inhibitor (atomoxetine) class)

McNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Methylphenidate extended-release; Atomoxetine — Competitive Intelligence Brief. https://druglandscape.com/ci/methylphenidate-extended-release-atomoxetine. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing